FDA Reviews Innovative Cancer Risk Tool for U.S. Use

A new medical device, designed to identify early cancer risks in patients, is currently under review by the Food and Drug Administration (FDA). The developers, C the Signs, aim to introduce this tool to the U.S. market next year, as revealed to Newsweek.

C the Signs: A Breakthrough in Early Cancer Detection

C the Signs is a device that assists healthcare professionals by analyzing a patient’s medical records to assess cancer risk without the need for additional tests or imaging. This early detection allows for referrals at the most treatable stages of cancer.

UK’s NHS Experience

The UK’s National Health Service (NHS) already employs this tool, with 11,000 professionals participating and 75,000 cancer cases identified. The tool has been shown to reduce diagnostic timelines by 21%.

Dr. Bea Bakshi, the co-founder and CEO of C the Signs, informed Newsweek that the FDA noted no existing product like C the Signs. This allows the device to pursue a De Novo classification, indicating it could be the first of its kind in the U.S.

While undergoing FDA review, the company plans to allow 250,000 Americans to participate in a study with the tool, according to Bakshi.

The FDA generally cannot confirm or deny pending product application details or statuses, as per a spokesperson from the Department of Health and Human Services who spoke to Newsweek.

Functionality and Advantages

Cancer screening usually covers only a small fraction of the 200+ cancer types, leading to complex diagnosis processes. C the Signs scans a patient’s complete medical history in under 60 seconds, identifying potential cancer risk patterns missed by clinicians. Dr. Bakshi explained that the device detects signs such as gradual changes in white blood cell counts, which might suggest cancer risk.

The tool’s models cater to individual cancer types, enhancing screening accuracy. It boasts a 99% negative predictive value for identifying cancer and a 94% accuracy rate for tumor origin prediction. Clinicians can swiftly act on risk assessments, streamlining the path to further diagnostic procedures.

Testimonials from patients and clinicians highlight the device’s ability to expedite diagnostics and improve patient care.

Potential Benefits for U.S. Healthcare

Gregory Simon, an adviser to C the Signs and former executive director of the White House Cancer Moonshot Task Force, told Newsweek that the tool offers early, precise cancer detection at a lower cost, thus reducing overall healthcare expenses and saving lives. He emphasized early adopter partnerships within the U.S. healthcare system for effective rollout and potential Medicare and Medicaid adoption.

Expert Opinions

Experts expressed a mix of cautious optimism and concern. Anant Madabhushi from Emory University noted the tool’s promising potential in the U.S., especially for those lacking access to specialist care. He emphasized the importance of validating the tool in U.S. populations due to differing healthcare systems.

The validity of C the Signs was supported by a Mayo Clinic study involving a million patients, showing potential pre-diagnosis identification for one in four patients.

Critiques arose from David Walt of Harvard Medical School, who raised concerns about possible false positives and the psychological stress of frequent risk updates.